Agenus Inc.

NasdaqCM:AGEN Stock Report

Market Cap: US$66.4m

Agenus Management

Management criteria checks 1/4

Agenus' CEO is Garo Armen, appointed in Jan 1994, has a tenure of 30.92 years. total yearly compensation is $5.86M, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth $506.26K. The average tenure of the management team and the board of directors is 2.9 years and 1.9 years respectively.

Key information

Garo Armen

Chief executive officer

US$5.9m

Total compensation

CEO salary percentage12.1%
CEO tenure30.9yrs
CEO ownership0.8%
Management average tenure2.9yrs
Board average tenure1.9yrs

Recent management updates

Recent updates

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29
Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22
Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09
News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04
A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10
Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Oct 12

Agenus New Trials Set It Up For The Long Haul

Sep 27

Agenus: It's Always Tomorrow

Sep 16

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Aug 09

Agenus: Successfully Pulled Itself Away From Disaster

Jul 04

Agenus: Not Quite Enough

Apr 19

Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Mar 06
Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Agenus: Making Another Effort With The FDA

Jan 25

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11
Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

CEO Compensation Analysis

How has Garo Armen's remuneration changed compared to Agenus's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$228m

Jun 30 2024n/an/a

-US$224m

Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$6mUS$710k

-US$246m

Sep 30 2023n/an/a

-US$271m

Jun 30 2023n/an/a

-US$263m

Mar 31 2023n/an/a

-US$240m

Dec 31 2022US$6mUS$689k

-US$220m

Sep 30 2022n/an/a

-US$215m

Jun 30 2022n/an/a

US$18m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$10mUS$655k

-US$24m

Sep 30 2021n/an/a

US$4m

Jun 30 2021n/an/a

-US$226m

Mar 31 2021n/an/a

-US$190m

Dec 31 2020US$6mUS$677k

-US$181m

Sep 30 2020n/an/a

-US$174m

Jun 30 2020n/an/a

-US$168m

Mar 31 2020n/an/a

-US$171m

Dec 31 2019US$10mUS$634k

-US$108m

Sep 30 2019n/an/a

-US$126m

Jun 30 2019n/an/a

-US$113m

Mar 31 2019n/an/a

-US$87m

Dec 31 2018US$3mUS$610k

-US$160m

Sep 30 2018n/an/a

-US$147m

Jun 30 2018n/an/a

-US$151m

Mar 31 2018n/an/a

-US$158m

Dec 31 2017US$4mUS$593k

-US$121m

Compensation vs Market: Garo's total compensation ($USD5.86M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Garo's compensation has increased whilst the company is unprofitable.

CEO

Garo Armen (71 yo)

30.9yrs

Tenure

US$5,856,319

Compensation

Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994. He serves as an Executive Chairman at MiNK Therapeutics, Inc. Dr. Armen serves as an Executive Chairman...

Leadership Team

NamePositionTenureCompensationOwnership
Garo Armen
Founder30.9yrsUS$5.86m0.76%
$ 506.3k
Christine Klaskin
VP of Finance18.2yrsUS$712.75k0.033%
$ 21.8k
Steven O'Day
Chief Medical Officer3.9yrsUS$1.44m0.058%
$ 38.5k
Craig Winter
Chief Information Officer2.9yrsno datano data
Zack Armen
Head of Investor Relations & Corporate Developmentless than a yearno datano data
Tracy Clemente
Chief People Officer2.9yrsno datano data
Alfred Dadson
Chief Manufacturing Officerno datano datano data
Eric Humes
Chief Quality Officer2.9yrsno datano data
Todd Yancey
Member of Advisory Board & Chief Strategic Advisor1.1yrsno datano data
Robin Taylor
Chief Commercial Officer1.4yrsno datano data
Nils Eckardt
Chief Medical Affairs Officerless than a yearno datano data
Jennifer Buell
Director and President & CEO of MiNK Therapeutics2.9yrsUS$7.42m0.058%
$ 38.7k

2.9yrs

Average Tenure

60.5yo

Average Age

Experienced Management: AGEN's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Garo Armen
Founder25.9yrsUS$5.86m0.76%
$ 506.3k
Todd Yancey
Member of Advisory Board & Chief Strategic Advisor1.9yrsno datano data
Jennifer Buell
Director and President & CEO of MiNK Therapeuticsless than a yearUS$7.42m0.058%
$ 38.7k
Thomas Harrison
Directorless than a yearno datano data
Robert Stein
Member of Advisory Board1.9yrsUS$1.04mno data
Timothy Wright
Independent Lead Director18yrsUS$385.50k0.012%
$ 7.8k
Larry Norton
Member of Advisory Board1.9yrsno datano data
Brian Corvese
Independent Director17.8yrsUS$888.14k0.020%
$ 13.0k
Susan Hirsch
Independent Director4.2yrsUS$242.00k0.025%
$ 16.8k

1.9yrs

Average Tenure

71yo

Average Age

Experienced Board: AGEN's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 22:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Agenus Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayank MamtaniB. Riley Securities, Inc.
Robert WassermanDawson James Securities